Stocks · News reference
Roivant Sciences shares are trading higher after the company announced its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease met its primary endpoint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52